Tarsus Pharmaceuticals Inc (TARS) Q4 2025 Earnings Call Highlights: Strong Financial …

GuruFocus News

Tue, February 24, 2026 at 2:01 PM GMT+9 3 min read

In this article:

TARS

+4.47%

This article first appeared on GuruFocus.

**Full Year Net Sales:** Over $450 million.

**Fourth Quarter Net Product Sales:** $151.7 million.

**Gross to Net Discount:** Approximately 44% for Q4 and 45% for the full year.

**Total Operating Expenses:** $522.3 million.

**Cash, Cash Equivalents, and Marketable Securities:** Approximately $419 million at year-end.

**2026 Net Product Sales Guidance:** $670 million to $700 million.

**Expected Gross Margin for 2026:** Approximately 93%.

**SG&A Expenses for 2026:** $545 million to $565 million.

**R&D Expenses for 2026:** $115 million to $135 million.

**Projected Annual Revenue Growth for 2026:** More than $230 million and 50% at the midpoint of guidance.

Warning! GuruFocus has detected 3 Warning Signs with TARS.

Is TARS fairly valued? Test your thesis with our free DCF calculator.

Release Date: February 23, 2026

For the complete transcript of the earnings call, please refer to the full earnings call transcript.

Positive Points

Tarsus Pharmaceuticals Inc (NASDAQ:TARS) reported over $450 million in net sales for 2025, highlighting strong financial performance.

XDEMVY, the first FDA-approved therapeutic for Demodex blepharitis, has helped over 0.5 million patients, showcasing its real-world impact.

The company anticipates XDEMVY reaching blockbuster status with sales potential exceeding $2 billion.

Tarsus Pharmaceuticals Inc (NASDAQ:TARS) plans to expand its pipeline by targeting 1 to 2 new programs per year, ensuring sustained growth.

The company has strong financial flexibility with approximately $419 million in cash, cash equivalents, and marketable securities.

Negative Points

Operating expenses were high at $522.3 million, driven by commercial investments for the XDEMVY launch.

The company expects first-quarter 2026 revenues to be flat or slightly below Q4 2025 due to typical seasonality and deductible resets.

Gross to net discount pressures are anticipated in Q1 2026, affecting revenue projections.

The company faces challenges in expanding its market internationally, with differences in pricing and reimbursement dynamics.

There is uncertainty regarding the exact timeline for achieving the $2 billion peak sales target for XDEMVY.

Q & A Highlights

Q: Can you give us more detail on your expectations beyond Q1 for the $370 million to $400 million guidance, particularly regarding bottles and refills? A: Bobak Azamian, CEO, explained that they expect flat to slightly down results in Q1 due to typical dynamics like deductible resets. Historically, there’s a bump in Q2, tempered growth in Q3, and robust growth in Q4. The guidance includes these dynamics, but they won’t provide specific model guidance unless there’s a material change.

Story Continues  

Q: As the launch continues, do you expect seasonal disruptions like conferences and weather to be as impactful? A: Aziz Mottiwala, Chief Commercial Officer, noted that as the launch progresses, typical seasonality will have more impact. However, the fundamentals are strong, with a growing base of prescribers and consumer awareness, which supports continued growth despite seasonal disruptions.

Q: Regarding the gross-to-net discount, where do you see it settling for the full year 2026? A: Jeffrey Farrow, CFO, stated that they expect some pressure in Q1 but anticipate the gross-to-net discount to stabilize in the 43% to 45% range by mid-year, similar to the 44% seen in Q4 2025.

Q: What is driving the increased conviction in the $2 billion peak sales target? A: Bobak Azamian, CEO, highlighted that XDEMVY’s performance over two years shows it as a breakthrough product. With only 0.5 million patients served out of 25 million potential, there’s significant room for growth. The transformation in eye care practice and flawless execution also contribute to this confidence.

Q: Can you provide more details on the Lyme disease program study design and endpoints? A: Seshadri Neervannan, COO, explained that the Phase IIb trial will enroll about 700 participants during peak season. They will measure safety and blood levels of lotilaner to assess TP-05’s effectiveness, aiming to create a strong Phase III-ready package.

For the complete transcript of the earnings call, please refer to the full earnings call transcript.

Terms and Privacy Policy

Privacy Dashboard

More Info